SUPPLEMENTARY TABLE S1. Exclusion criteria

| Medical history | Prior treatment with |
| --- | --- |
| * History of allergy to salicylates, aminosalicylates, or any component of the administered study drug | * Immunomodulatory therapy including, but not limited to: rosiglitazone, 6-mercaptopurine or azathioprine, cyclosporine, or methotrexate within 90 days prior to screening visit |
| * Malabsorption, any condition bearing an effect on gastrointestinal motility | * Biologic therapy including, but not limited to: infliximab, certolizumab, adalimumab or other biologic treatment of ulcerative colitis within 90 days prior to screening visit |
| * A history of extensive small bowel resection causing short bowel syndrome | * Any oral, intravenous, intramuscular, or rectally administered corticosteroids (including budesonide) within 30 days prior to the screening visit |
| * Significant co-existing illness such as cancer, significant organic or psychiatric disease that contraindicated administration of the study drug | * Any other topical (non-oral) mesalamine therapy within 7 days prior to the screening visit |
| * Current renal disease, a screening BUN or creatinine value that is >1.5 × ULN | * Antibiotics (other than topical antibiotics) including metronidazole within 7 days prior to the screening visit |
| * Documented history of or current hepatic disease, liver function tests (e.g. ALT, AST, bilirubin) that were >2 × ULN | * Aspirin or other non-steroidal anti-inflammatory drugs within 7 days prior to the screening visit |
| * History of pancreatitis, clinically significant laboratory test value abnormality that would impact the outcome of the study or the safety of the patient | * Any anti-diarrheal medication and/or antispasmodics within 3 days of the screening visit |
| * A stool examination positive for *Clostridium difficile*, bacterial pathogens, or ova and parasites |  |

ALT = alanine transaminase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; ULN = upper limit of normal.